{
  "docId": "019de076-9434-73df-8e70-401e13bb3d65",
  "docSlug": "692690be0ea25b83b6a4c7490ff14999",
  "documentTitle": "BioAtla | Investor Presentation Deck | 55 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 55,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The diagram illustrates a dose escalation study design with combination therapy.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-9434-73df-8e70-401e13bb3d65/12",
  "deckHref": "/decks/019de076-9434-73df-8e70-401e13bb3d65",
  "deckJsonHref": "/decks/019de076-9434-73df-8e70-401e13bb3d65.json",
  "deckAnchorHref": "/decks/019de076-9434-73df-8e70-401e13bb3d65#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.8,
        "w": 0.315,
        "x": 0.648,
        "y": 0.075
      },
      "kind": "chart",
      "text": "Combination Therapy (Q3W) dose levels from 7mg to 700mg",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0462b4b0-cd08-4e66-ae39-a7573528c402",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.25,
        "x": 0.65,
        "y": 0.82
      },
      "kind": "legend",
      "text": "BA3071; BA3071 + 240 mg nivolumab",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c9af97e5-bfcb-40ba-b9a9-bbb56db94a7d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.1,
        "y": 0.19
      },
      "kind": "list",
      "text": "Key Objectives: Define safety profile and determine Phase 2 dose and MTD; Evaluate antitumor activity and immunogenicity; Determine PK parameters",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4ed7fdf3-bfec-488e-a274-8e7da4be6490",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.45,
        "x": 0.1,
        "y": 0.43
      },
      "kind": "list",
      "text": "Key Eligibility Criteria: CTLA-4 naïve; Treatment refractory: melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, urothelial cancer, gastric cancer, hepatocellular carcinoma (HCC), cervical cancer, small cell lung cancer (SCLC)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5d66f3d9-d128-4bc2-b759-2eb856e97831",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.26,
        "x": 0.635,
        "y": 0.94
      },
      "kind": "paragraph",
      "text": "Further dose escalation planned to 1,000 mg",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "48b70017-3c0e-4c3d-8dd3-3c56743fd713",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.55,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Phase 1 CAB-CTLA-4 (BA3071) Dose Escalation",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "975e5e50-87ff-4531-a73a-8e0dd0fefd94",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "e68968e6-bd90-4060-a33c-a9a527d8708d",
      "evidence": "The dose escalation diagram functions as a timeline/process flow for clinical trial progression.",
      "confidence": 0.6
    }
  ],
  "arcBeats": [
    {
      "to": 21,
      "from": 11,
      "beatId": "4a9f5223-f601-412c-b3bc-2e7d0fdbbb91",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The traction section spans pages 11-21, showcasing clinical trial results and progress.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 21,
      "from": 8,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "d33db2f2-b823-454e-bb8a-d3c7565f8111",
      "evidence": "The traction section on pages 8-21 highlights quick wins and big bets.",
      "position": 1,
      "objective": "Showcase quick wins and big bets in CAB development",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    },
    {
      "to": 21,
      "from": 11,
      "name": "Voice Of Customer",
      "slug": "51-voice-of-customer",
      "bestFor": "Product strategy, customer experience, market research",
      "matchId": "6accda1b-f475-4991-8a77-17e1fdfaad42",
      "evidence": "Clinical trial results on pages 11-21 demonstrate customer benefit.",
      "position": 2,
      "objective": "Provide evidence of customer (patient) benefit",
      "structure": "What Customers Say (Verbatim) -> The Pattern Across Voices -> The Insight -> The Response",
      "confidence": 0.6,
      "description": "Let customer quotes and feedback drive the narrative and validate the insight"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}